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Abstract
Background: Ameloblastoma is an odontogenic neoplasm characterized by local invasiveness and tendency
towards recurrence.
Aims: Studying the role played by EGFR, CD10 and Ki67 in the recurrence of ameloblastoma.
Methods: This study was carried out on 22 retrospective cases of mandibular ameloblastoma from the period from
Jan 2002 to Jan 2008 with follow up period until Jan 2011 (3 to 8 years follow up peroid). Archival materials were
obtained from pathology department, Mansoura university. Paraffin sections of tumor tissue from all cases were
submitted for routine H&E stains and immunohistochemistry using EGFR, CD10 and Ki67 monoclonal antibodies.
Statistical analysis using of clinical data for all patients, tumor type, EGFR, CD10 and Ki67 expression in relation to
recurrence were evaluated.
Results: Among the 22 cases, 10 cases were males and 12 were females with sex ratio 1:1.2. Age ranged from 34
to 59 years old with a mean age 44.18 year. Five cases showed local recurrence within studied period and proved
by biopsy. No statistically significant relation was found between local recurrence and patient age, tumor size,
tumor type, EGFR expression. There was a significant relation between CD10 expression as well as Ki67 labelling
index and recurrence (P value = 0.003, 0.000 respectively).
Conclusion: Evaluation of CD10 and Ki67 status together with conventional histological evaluation can help in
providing more information about the biologic behavior of the tumor, while EGFR could be a target of an
expanding class of anticancer therapies.
Since ameloblastomas are EGFR-positive tumors, anti-EGFR agents could be considered to reduce the size of large
tumors and to treat unresectable tumors that are in close proximity to vital structures.
Virtual Slides: The virtual slide(s) for this article can be found here:
http://www.diagnosticpathology.diagnomx.eu/vs/1902106905645651
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Introduction
Ameloblastoma is the most common odontogenic neo-
plasm that accounts for about 1% of all oral tumors [1]
and arises from the epithelium of the dental lamina
affecting mainly the posterior mandible (80%) and to a
lesser extent the posterior maxilla (20%). It usually affects
adults in the 4th - 5th decades of life [2]. Ameloblastoma
is generally benign, grows slowly and is not associated
with symptoms until it becomes large. However, it is
locally aggressive and displays a strong tendency to recur
especially if not adequately removed [3,4] and even
metastasize in rare conditions[5]. It is important to assess
the type according to recent WHO classification (solid/
multicystic, unicystic, desmoplastic and peripheral), loca-
lization, and size of the tumors as well as age of the
patient [6]. There are two basic histopathologic patterns;
the follicular and plexiform without clinical relevance [7].
The epidermal growth factor receptor (EGFR) is a
transmembrane receptor tyrosine kinase comprising an
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domain, and an intracellular tyrosine kinase domain [8].
Binding of epidermal growth factor results in EGFR
dimerization and subsequent activation of the intrinsic
tyrosine kinase activity. Phosphorylated EGFR concomi-
tantly triggers downstream mitogenic signaling via both
the MAPK and PI3K pathways [9].
Expression of epidermal growth factor receptor
(EGFR) regulates proliferation of both normal and neo-
plastic cells [10,11]. It has been observed in normal
epithelia, including the oral mucosa, and might provide
epigenetic control of odontogenesis [12].
CD10 (common acute lymphoblastic leukemia antigen,
CALLA) is a 100-kDa transmembrane glycoprotein, also
known as neutral endopeptidase (NEP), involved in the
cleavage and inactivation of certain peptide hormones
important for signal transduction [13]. CD10 is
expressed by a variety of normal cell types, including
lymphoid precursor cells, germinal center B lymphocytes
and some epithelial cells as gastric mucosa [14]. First,
CD10 was reported in relation to lymphoid neoplasms.
However, its expression is also reported in malignant
epithelial neoplasm and melanoma [15]. Although CD10
expression is observed in neoplastic cells, there are
reports of its expression in stromal cells. Moreover,
there are cumulative data indicating that CD10 expres-
sion by stromal cells is involved in carcinogenesis and it
is supposed to be a novel prognostic factor in some
malignant tumors [14].
Identification of proliferating activities in tumors may
be useful to predict their biological behavior. Ki-67 pro-
tein is a nuclear non-histone protein which is required
for maintaining the cell cycle. Ki-67 is expressed by pro-
liferating cells in all phases of the active cell cycle (G1,
S, G2 and M phase) but is absent in resting (G0) cells
[16]. Ki-67 has been used to determine the proliferation
rate of many tumors, including ameloblastomas [17].
For a better understanding of the aggressive behavior
of ameloblastomas, their expression of growth factor
receptors, metalloproteinases and their proliferative
activity have been investigated using immunohistochem-
ical methods. So, the aim of the present study is evalua-
tion of EGFR, CD10 expression and Ki-67 labelled index
in ameloblastoma and their relation to recurrence.
Materials and methods
This retrospective study was carried out on mandibular
ameloblastoma specimens received in the pathology
department from the period from Jan 2002 to Jan 2008.
Follow up data were retrieved from patient’sf i l e sf o ra t
least 3 years duration. Each specimen was coded and
patient’s name was not shown for ethical reasons. Age
of the patients, sex, tumor size, site and recurrence were
revised.
Ethical approval of this study was not required by our
institution as this study was based on retrospective ana-
lysis dealing with archival paraffin slides and blocks, not
related to patient’s privacy, impairment or treatment.
Histopathology
Sections of 4 um thickness have been cut from formalin
fixed paraffin embedded blocks of archival ameloblas-
toma tissues for routine H&E, others were prepared on
charged slides for immunohistochemistry. Examination
of three tumor slides from each specimen were done on
an Olympus CX31 light microscope. Pictures were
obtained by a PC-driven digital camera (Olympus E-620).
The computer software (Cell*, Olympus Soft Imaging
Solution GmbH) allowed morphometric analysis to be
performed.
Immunohistochemistry
Immunohistochemical analysis for EGFR, CD10 and KI67
with a labelled streptavidin- biotin-peroxidase complex
technique was performed on tumor sections. The antibo-
dies used were monoclonal antibody against EGFR (clone
H11-DAKO, DakoCytomation, Carpinteria, CA, USA), at
1:25 dilution, CD10 (Santa Cruz Biotechnology Inc., sc-
19993, dilution 1: 50) and Ki-67 (clone MIB-1, N1633,
Dako Corporation, Carpinteria, CA, USA, RTU). Detection
kit used was high sensitive kit (DakoCytomation envision
+dual link system peroxidase code K4061) using DAB as
chromogene. EGFR immunostaining required antigen
retrieval with 0.2% trypsin, CD10 and Ki67 immunostain-
ing required pretreatment with 1 mM EDTA (at pH 8.0)
for 20 minutes in microwave oven. Proper positive and
negative controls were performed. Normal oral mucosa
was used as positive control for EGFR, tonsils for Ki67
and CD10. As a negative control, sections were stained
without the addition of a primary antibody.
Immunohistochemical Analysis
As for the immunohistochemistry assessment, Slides
were scanned by X40 magnification. Ten cellular areas
selected (i.e. the so-called hot spots) and evaluated at
X400 magnification by two pathologists.
Assessment of EGFR
Both membranous and cytoplasmic staining of EGFR
were evaluated. The proportion of stained cells and
staining intensity were combined to assess the immuno-
histochemical staining according to previous records
[18-20]. Staining intensity was evaluated on a semi-
quantitative three-point scale: 0–no staining, 1–weak
and 2–strong staining. The final EGFR staining score
was calculated by multiplying the percentage of posi-
tively stained tumor cells by the staining intensity.
Accordingly, the highest score for a given tumor would
be equal to 2.
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Stromal CD10 was scored according to similar system
suggested by Iwaya et al, [21]. and Zu et al. [22]. as fol-
low 0, equivalent to the negative control; 1, weak cyto-
plasmic stain; 2, moderate stain; 3, intense stain. The
percentage of stained cells was also scored on a semi-
quantitative 4-point scale as: 0, < 10%; 1, 10-25%; 2, 25-
5 0 % ;3 ,>5 0 % .T h e n ,c o m b i n i n gt h es c o r eo fs t a i n i n g
intensity and percentage of stained cells: a score of 0-1
was -, 2 was +, 3-4 was ++ and 5-6 was +++.
Assessment of Ki67
Ki67 labeling index was done by calculating the ratio of
positive nuclei in relation to total number of neoplastic
nuclei in 10 HPFs. The labeling index (number of posi-
tive tumor cells/total number of tumor cells expressed
as a percentage) was calculated in every specimen [23].
Statistical analysis
All parameters included age, tumor size, pathologic type,
EGFR, CD10 expression in stromal cells and ki67 label-
ing index with recurrence were evaluated by statistical
analysis. The statistical analysis of data was done by
using statistical package for social science (SPSS) pro-
gram version 14. Descriptive statistics were done. The
presented data was asymmetrical. One Way Anova test
(for EGFR, Ki67) and Chi square test (for the remaining
data including CD10) were performed to determine sig-
nificance of the relations. Survival analysis of recurrence
free survival was done by Kaplan-Meier analysis and log
rank test was used for comparison between groups.
Probability (p) values < 0.05 were considered significant.
Results
This study was carried out on retrospective cases man-
dibular ameloblastoma received in the pathology depart-
ment from the period from Jan. 2002 to Jan. 2008 with
follow up period until Jan. 2011 (minimal 3 years follow
up).
Clinical characteristics
Ten cases were males and 12 were females with sex
ratio 1:1.2. Age ranged from 34 to 59 years old with
mean age 44.18 ± 6.97. Five cases (22.7%) showed local
recurrence, four of them recurred 3-5 years after resec-
tion and one case recurred 2 years after
Pathology results
Sixteen cases were follicular and six cases were plexi-
form subtype. As shown in table (1), all specimens
demonstrated EGFR-positively stained tumor cells.
Staining was membranous and cytoplasmic, both periph-
eral and central cells were stained (Figure 1). Two cases
(9.1%) exhibited the maximum score of 2 and 20
(90.9%) scored between 0.2 and 1.8. Stromal CD10
immunostaining was negative in one case, 11 cases were
(+), 7 cases were (++), 3 cases were (+++) (Figure 2).
Regarding Ki67 labeling index, 17 cases showed low
index with mean 8.29 ± 3.15 and 5 cases showed high
index with mean 19 ± 2.12 (Figure 3).
Table (2) showed no statistically significant association
between local recurrence and patient age (p = 0.774),
tumor size (p = 0.375), tumor types (p = 0.467), and
EGFR score (p = 0.774). There was a statistically signifi-
cant relation between stromal CD10 and recurrence
(P = 0.003); the stronger expression is associated with
recurrence. Statistically significant relation was found
between Ki67 labeling index and recurrence (P < 0.001);
cases with recurrent ameloblastoma showed higher
index (mean 19 ± 2.12) in contrast to non-recurrent
cases (mean 8.29 ± 3.15).
During the follow-up period, three cases having short
recurrence free survival (RFS) (2-3 years) showed
marked stromal CD10 expression (+++) and higher Ki67
labeling indices (19-22). On the other hand, cases with
longer RFS (5, 7 years) showed moderate stromal CD10
expression (++) and less Ki67 labeling indices (17, 18).
A statistically significant decrease in Patient’sR F Sw a s
associated with stromal CD10 expression (P < 0.001 by
Table 1 Summary of clinicopathologic finding of the
studied cases.
No Age Sex Size
(cm)
Pathological
type
EGFR CD
10
Ki67 Recurrence
1 46 M 5 Plexiform 0.4 + 9 -
2 37 F 4 Plexiform 0.9 ++ 6 -
3 34 M 4 Tubular 1.6 + 6 -
4 38 M 3 Tubular 1 ++ 17 +
5 48 F 4 Plexiform 2 +++ 20 +
6 42 M 5 Plexiform 1.6 + 5 -
7 48 M 3 Plexiform 1.2 + 7 -
8 52 F 6 Tubular 0.2 ++ 18 +
9 47 M 4 Plexiform 0.5 ++ 4 -
10 45 F 6 Plexiform 1.3 ++ 16 -
11 46 M 5 Plexiform 0.3 +++ 22 +
12 45 F 6 Plexiform 1.5 +++ 19 +
13 59 M 3 Tubular 1.8 - 11 -
14 35 F 4 Plexiform 1 ++ 9 -
15 43 F 3 Tubular 1.5 + 10 -
16 39 F 4 Plexiform 0.8 + 6 -
17 49 M 5 Plexiform 2 + 6 -
18 36 F 2 Plexiform 1.2 + 7 -
19 59 M 4 Tubular 0.2 + 9 -
20 46 F 5 Plexiform 1.4 + 14 -
21 42 F 2 Plexiform 2 + 7 -
22 36 F 4 Plexiform 0.6 ++ 9 -
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showing mild stromal CD10 expression, 7.4 ± 0.43 in
cases showing moderate stromal CD10 expression, 2.7 ±
0.33 in cases showing mild stromal CD10 expression
(Figure 4). A statistically significant decrease in Patient’s
RFS was associated with Ki67 labeling index (P < 0.001
by Log-Rank test). The mean RFS was 8 ± 0.1 in cases
with Ki67 index < 10, 5.1 ± 0.96 in cases with Ki67
index > 10 (Figure 5).
Discussion
Ameloblastomas are locally invasive and destructive
benign odontogenic tumors that arise from rests of the
dental lamina. Their recurrence rate is high [3,4] even
for patients that undergo surgical excision of the tumor
even in excised tumors with free safety margin. The
immunohistochemistry can describe the biological dif-
ferences of these tumor types [24]. This study was car-
ried out to elucidate the relationship between the
expression of EGFR, CD10 and Ki-67 labelled index and
ameloblastoma recurrence using clinical and pathologi-
cal data.
Normal EGFR signaling plays an essential role in
organ development, repair and in the regulation of cell
survival. Aberrant signaling can be the result of EGFR
overexpression by EGFR gene amplification or muta-
tions with ligand-independent tyrosine kinase activity
which could result in uncontrolled cell division; a pre-
disposition for cancer [25,26]. EGFR upregulation
appeared to be selectively expressed in a number of
tumors as glioblastomas and lung cancer [27].
In the current study, all ameloblastomas exhibited
EGFR immunoexpression with no identified relation to
recurrence. Previous studies in the literature evaluated
EGFR expression in ameloblastomas [19,28,29], and
their results were divergent. Shrestha et al. [28] claimed
that of the 23 cases of examined solid ameloblastomas,
none demonstrated EGFR expression. However, Li et al.
[29] reported that EGFR was detected in all six of their
cases of ameloblastoma. Ueno et al., [30] examined 39
cases of solid ameloblastoma and EGFR expression was
found in 30 (88%). Vered et al., [19] reported that all
specimens were EGFR-positive using membranous, or
both membranous and cytoplasmic staining as positivity
Figure 1 EGFR immunostaining (A) represents membranous and cytoplasmic EGFR expression in basal and stellate reticulum like cells. (B)
represents membranous and cytoplasmic EGFR expression in focus of squamous differentiation (immunoperoxidase X200).
Figure 2 Stromal CD10 immunostaining (A) represents cytoplasmic and nuclear CD10 expression of mild intensity in about 15% of stromal
cells. (B) represents CD10 expression of moderate to strong intensity in about 70% of stromal cells (immunoperoxidase X200).
Abdel-Aziz and Amin Diagnostic Pathology 2012, 7:14
http://www.diagnosticpathology.org/content/7/1/14
Page 4 of 7criteria. Our results were mainly consistent with the lat-
ter finding. The differences between previous reports
may be explained by the different positivity criteria
adopted, such as only membrane labeling [28], or mem-
brane and cytoplasmic labeling associated with labeling
intensity [19,29].
CD10 is associated with differentiation and growth of
neoplastic cells, and its expression is found to be
increased with the increase of tumor dysplasia. Ogawa et
al., [31] found that there was no expression of CD10 in
the stromal cells of normal colorectal tissue, while the
percentage of CD10+ stromal cells were increasing adja-
cent to tumor cells with increasing dysplasia in adeno-
mas and maximally found in stroma adjacent to invasive
carcinoma [32]. Iwaya et al., [19] found that there was
no staining in the stromal cells of noninvasive ductal
carcinoma or normal breast tissue, while the frequency
of positive stromal staining increased in cases with axil-
lary lymph node metastases [21]. In the study of Mak-
retzov et al., [32] stromal CD10 positivity, seen at the
Figure 3 Nuclear KI67 immunostaining (A) represents Ki 67 labeling index reaching 7% of neoplastic cells. (B) represents Ki 67 index reaching
20% of neoplastic cells (immunoperoxidase X200).
Table 2 Demographic and pathologic criteria of studied cases in relation to recurrence.
Non recurrent
Cases(No)
Recurrent
Cases(No)
P Value
Age groups (years) 6 1 0.774
30-40 9 3
40-50 2 1
50-60
Tumor size (cms) < 2 5 1 0.375
2-5 7 1
5-7 4 2
7-9 1 1
Histological type Follicular Plexiform 13 3 0.467
42
EGFR Expression No 17 5 0.775
Mean 1.07 ± 0.56 0.98 ± 0.70
Median 11
Range 0.2-2(1.8) 0.1-2(1.9)
CD10 Expression 0 1 0 0.003
+ 11 0
++ 52
+++ 03
Ki67 Index No 17 5 0.000
Mean 8.29 ± 3.15 19.00 ± 2.12
Median 7
Range 4-16(12) 19
17-22(18)
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and decreased survival in breast carcinoma, suggesting
tumor-stromal interactions. In a study of CD10 in oral
squamous cell carcinoma, it was found that CD10 posi-
tivity in stromal cells was an indicator of worse prog-
nosis; a significant correlation was found with lymph
node metastases, local recurrences, and histologic grade
[33].
Ameloblastoma is a tumor that shows heterogeneous
expression of CD10 [34]. Most recurrent tumors strongly
express CD10 and could be a marker for aggressive beha-
vior. Our data demonstrated that patients with tumors
strongly express CD10 in the peritumoral stromal cells
were more prone to local recurrence after resection with
uninvolved cut margins. This is similar to the results in
studies done by Lezzi et al., [35] and Masloub et al., [36].
It is possible then that the function of CD10 is employed
primarily in invasion of extracellular matrix. The pre-
sence of CD10+ stromal cells may signify the aggressive-
ness of tumor. Similarly, Bilalovic et al., [37] reported
metastatic behavior of melanoma cases with peritumoral
CD10 positive stain.
Assessment of cell proliferation in many types of
tumors is important together with histologically based
tumor classification and has potential relevance as an
indicator of tumor behavior, treatment response and
relapse [38]. The results of this study showed that cellu-
lar proliferative activity as assessed by Ki67 labeling
indices varied within recurrent and non-recurrent cases
of ameloblastoma. There was a significant relation
between labeling index of nuclear proliferation marker
ki67 and recurrence of ameloblastoma. This is in con-
cordance with Hirayama et al., [39] who found a high
proliferative activity in recurrent ameloblastoma. In this
study, the assessment of the cellular proliferation marker
was shown to be reliable and reproducible.
All the above-mentioned immunohistochemical data
indicated that the immunoexpression of CD10 and Ki67
labeling index may be good predictor for recurrence in
ameloblastoma.
Conclusion
Our data demonstrated that CD10-positive tumors with
high Ki67 index were associated with high recurrence
rate, while EGFR expression was not predictive for prog-
nosis in ameloblastomas but may render such tumors
candidate for the new targeted anti-EGFR treatment
modalities. Moreover, we hope formulation of a target
therapy against CD10 positive cells, including monoclo-
nal antibody mediated-delivery of chemotherapy. Clini-
cal surveys with larger study cohorts will be needed to
verify our findings.
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